1. Home
  2. AORT vs MNKD Comparison

AORT vs MNKD Comparison

Compare AORT & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Artivion Inc.

AORT

Artivion Inc.

HOLD

Current Price

$26.88

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Logo MannKind Corporation

MNKD

MannKind Corporation

HOLD

Current Price

$3.97

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AORT
MNKD
Founded
1984
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
1996
2004

Fundamental Metrics

Financial Performance
Metric
AORT
MNKD
Price
$26.88
$3.97
Analyst Decision
Strong Buy
Buy
Analyst Count
5
8
Target Price
$49.40
$8.69
AVG Volume (30 Days)
719.0K
4.2M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
165.62
N/A
EPS
N/A
N/A
Revenue
$298,836,000.00
$348,966,000.00
Revenue This Year
$14.20
$35.81
Revenue Next Year
$11.20
$11.89
P/E Ratio
N/A
N/A
Revenue Growth
18.01
22.23
52 Week Low
$19.16
$2.23
52 Week High
$48.25
$6.51

Technical Indicators

Market Signals
Indicator
AORT
MNKD
Relative Strength Index (RSI) 49.27 48.70
Support Level $25.79 $3.74
Resistance Level $28.29 $4.23
Average True Range (ATR) 1.15 0.17
MACD -0.31 -0.00
Stochastic Oscillator 20.02 45.30

Price Performance

Historical Comparison
AORT
MNKD

About AORT Artivion Inc.

Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.

About MNKD MannKind Corporation

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Share on Social Networks: